1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
United States
(512) 614-1848
https://www.savarapharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 37
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO | 970k | N/D | 1971 |
Mr. David L. Lowrance CPA | CFO, Chief Administrative Officer & Secretary | 667,4k | N/D | 1968 |
Mr. Robert Lutz M.B.A. | Chief Operating Officer | 723,55k | N/D | 1970 |
Ms. Kate McCabe J.D. | Senior VP & General Counsel | N/D | N/D | N/D |
Ms. Anne Erickson | Chief Business Officer | N/D | N/D | 1972 |
Brian Maurer | Head of Clinical Operations | N/D | N/D | N/D |
Mr. Charles LaPree | Senior Vice President of Global Regulatory Affairs & Quality Assurance | N/D | N/D | N/D |
Dr. Peter Clarke Ph.D. | Executive Vice President of Global Technical Operations | N/D | N/D | 1960 |
Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer | 91,89k | N/D | 1951 |
Mr. Scott L. Wilhoit | Executive Vice President of Global Commercial | N/D | N/D | 1963 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
L'ISS Governance QualityScore di Savara Inc. al 1 maggio 2024 è 4. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 6; diritti degli azionisti: 1; retribuzione: 7.